<div id="readability-page-1"><p>Cwm LLC lifted its position in  BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 46.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 87,955 shares of the biotechnology company's stock after acquiring an additional 27,894 shares during the quarter. Cwm LLC's holdings in BioMarin Pharmaceutical were worth $4,835,000 at the end of the most recent reporting period.</p><ul><li>Can BioMarin Stock Live Up to Wall Street’s High Expectations?</li></ul><p>Other institutional investors have also recently made changes to their positions in the company. V Square Quantitative Management LLC bought a new stake in shares of  BioMarin Pharmaceutical in the 2nd quarter worth $25,000.  Farther Finance Advisors LLC grew its stake in shares of  BioMarin Pharmaceutical by 95.9% in the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 211 shares in the last quarter.  Rise Advisors LLC bought a new stake in shares of  BioMarin Pharmaceutical in the 1st quarter worth $30,000.  Brooklyn Investment Group grew its stake in shares of  BioMarin Pharmaceutical by 2,250.0% in the 1st quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 540 shares in the last quarter.  Finally, Banque Transatlantique SA bought a new stake in shares of  BioMarin Pharmaceutical in the 1st quarter worth $71,000. Institutional investors own  98.71% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><p>BMRN has been the subject of several recent analyst reports. UBS Group upped their target price on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, August 5th. Morgan Stanley cut their price target on shares of BioMarin Pharmaceutical from $97.00 to $96.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, July 22nd. Guggenheim boosted their price target on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, August 6th. Weiss Ratings  reissued a &#34;sell (d+)&#34; rating on shares of BioMarin Pharmaceutical in a report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of BioMarin Pharmaceutical from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, August 13th. Thirteen research analysts have rated the stock with a Buy rating, eight have assigned  a Hold rating and one  has issued  a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $93.26.</p><ul><li>3 Oversold Stocks with Big RSI Rebound Potential</li></ul><p><b>Check Out Our Latest Analysis on BMRN</b></p><h2>BioMarin Pharmaceutical Price Performance</h2><p>BMRN opened at $52.95 on Friday. The company has a market capitalization of $10.17 billion, a price-to-earnings ratio of 15.71, a PEG ratio of 0.67 and a beta of 0.33. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10. The firm has a 50-day moving average price of $55.74 and a 200-day moving average price of $57.67. BioMarin Pharmaceutical Inc. has a twelve month low of $51.56 and a twelve month high of $73.51. </p><h2>BioMarin Pharmaceutical Company Profile</h2> (Free Report)<ul><li>Are Gene Therapy Stocks The Market's Next Big Winners?</li></ul><p>BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.</p><h2>Read More</h2><ul><li>Five stocks we like better than BioMarin Pharmaceutical</li><li>Why Invest in 5G? How to Invest in 5G Stocks  </li><li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li><li>3 REITs to Buy and Hold for the Long Term</li><li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li><li>What Are Growth Stocks and Investing in Them </li><li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li></ul><p><strong>Want to see what other hedge funds are holding BMRN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in BioMarin Pharmaceutical Right Now?</h2><p>Before you consider BioMarin Pharmaceutical, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.</p><p>While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

BMRN

<p>Cwm LLC increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 46.4% in Q2, acquiring an additional 27,894 shares, bringing its total to 87,955 shares valued at $4.83 million. Other institutional investors also adjusted their positions. Analysts have mixed ratings on BMRN, with a target price range from $93.26 to $114.00. The stock opened at $52.95, with a market cap of $10.17 billion and a 12-month range of $51.56 to $73.51. BioMarin specializes in therapies for rare diseases.</p>

Cwm LLC Purchases 27,894 Shares of BioMarin Pharmaceutical Inc. $BMRN